Engineered immune cells take aim at Hard-to-Treat cancers

This trial investigates a new type of immunotherapy for people with advanced cancers that carry a specific marker called NY-ESO-1. Researchers take a patient's own T cells, modify them in the lab to better recognize and attack cancer cells, and then infuse them back. The study also tests whether adding a chemotherapy drug called decitabine can make the modified T cells work better. The goal is to find the safest dose and see if this approach can shrink tumors or slow the disease.